Mobile

International, randomized, open-label, Phase 3 trial of gemcitabine/cisplatin plus PF-3512676 versus gemcitabine/cisplatin alone as first-line treatment of patients with advanced non-small cell lung c...

Update Il y a 4 ans
Reference: EUCTR2005-004557-10

International, randomized, open-label, Phase 3 trial of gemcitabine/cisplatin plus PF-3512676 versus gemcitabine/cisplatin alone as first-line treatment of patients with advanced non-small cell lung cancer

Woman and Man

  • | Country :
    • -
  • | organs :
    • -
  • | Specialty :
    • -

Extract

- To compare overall survival (OS) in patients randomized to gemcitabine/cisplatin + PF-3512676 (Investigational Treatment Arm) versus that in patients randomized to gemcitabine/cisplatin alone (Control Treatment Arm)

Inclusion criteria

  • First line treatment of chemotherapy-naive patients with locally advanced (Stage IIIB with pleural effusion) or metastatic (Stage IV) Non Small Cell Lung Cancer (NSCLC)

Links